Wet Age-Related Macular Degeneration

SAN FRANCISCO — Rahul Khurana, MD, of Northern California Retina Vitreous Associates, shared the 2-year results from the CEDAR and SEQUOIA studies, which showed abicipar given every 12 weeks and every 8 weeks was equivalent to ranibizumab every 4 weeks for neovascular age-related macular degeneration at the American Academy of Ophthalmology annual meeting.

The first patient has been dosed in the third cohort of the OPTIC phase 1 clinical trial of ADVM-022, an intravitreal gene therapy for the treatment of wet age-related macular degeneration, according to a press release from Adverum Biotechnologies.

SAN FRANCISCO — Faricimab demonstrated sustained inhibition of both angiopoietin-2 and VEGF-A in patients with neovascular age-related macular degeneration, according to a presentation at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.

SAN FRANCISCO — Patients with wet age-related macular degeneration in the OPTIC trial treated with one in-office injection of ADVM-022, a gene therapy specifically designed for long-term intraocular VEGF suppression, maintained best corrected visual acuity and experienced improved central subfield thickness from baseline through 24 weeks’ follow-up, according to a speaker here.

Graybug Vision initiated a phase 2b study of GB-102, a pan-VEGF receptor inhibitor and potential twice-per-year therapy, for the treatment of wet age-related macular degeneration.

Novartis announced a phase 3b clinical trial to evaluate brolucizumab vs. aflibercept in the treatment of wet age-related macular degeneration.

To better help patients with wet age-related macular degeneration continue to live independently, Novartis recently partnered with celebrity interior designer Nate Berkus to create the program My Home in Sight.

Patients treated with OPT-302 from Opthea Limited plus ranibizumab demonstrated better anatomical changes over those treated with ranibizumab alone in a phase 2b study.

The FDA has accepted a biologics license application and the European Medicines Agency has validated a marketing authorization application for abicipar pegol, an investigational DARPin therapy for wet age-related macular degeneration, Allergan and Molecular Partners announced in a press release.

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space.